Staar Surgical (STAA) EBITDA Margin (2010 - 2026)

Staar Surgical (STAA) has reported EBITDA Margin for 17 consecutive years, with 10.8% the latest figure, recorded in Q3 2026.

• For the quarter ending Q3 2026, EBITDA Margin rose 7841.0% year-over-year to 10.8%; the trailing twelve-month figure through Jul 2026 stood at 4.04% (up 5287.0% YoY), and the FY2026 full-year result was 38.3%, down 3429.0% from the prior year.
• EBITDA Margin rose to 10.8% in Q3 2026 per STAA's latest filing, from 8.53% in the prior quarter.
• Across five years, EBITDA Margin topped out at 20.99% in Q3 2022 and bottomed at 134.78% in Q1 2025.
• Historically, EBITDA Margin has averaged 8.15% across 5 years, with a median of 8.19% in 2023.
• The sharpest annual moves came in 2025 and 2026: EBITDA Margin sank 13183 bps in 2025, then jumped 14331 bps in 2026.
• Over 5 years, EBITDA Margin stood at 5.05% in 2022, then surged by 170 bps to 13.64% in 2023, then slumped by 518 bps to 57.02% in 2024, then jumped by 134 bps to 19.52% in 2025, then slumped by 45 bps to 10.8% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 10.8%, 8.53%, and 39.51% for Q3 2026, Q2 2026, and Q1 2026 respectively.